Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTSNASDAQ:AMRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTSAkoustis Technologies$0.07$0.03▼$1.19$10.54M1.9139.87 million shs118.70 million shsAMRNAmarin$0.40-14.9%$0.55$0.35▼$1.11$164.31M1.821.44 million shs15.67 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTSAkoustis Technologies0.00%0.00%0.00%-52.79%-94.04%AMRNAmarin+1.12%-7.78%-13.05%-0.04%-47.49%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTSAkoustis TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AAMRNAmarin0.4 of 5 stars0.02.00.00.02.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTSAkoustis Technologies 0.00N/AN/AN/AAMRNAmarin 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTSAkoustis Technologies$27.38M0.00N/AN/A($0.46) per share0.00AMRNAmarin$241.02M0.68N/AN/A$1.35 per share0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTSAkoustis Technologies-$167.95MN/A0.00N/AN/A-524.47%-584.18%-166.76%N/AAMRNAmarin-$59.11M-$0.09N/AN/AN/A-16.33%-7.22%-4.96%3/12/2025 (Estimated)Latest AKTS and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2025Q4 2024AMRNAmarin-$0.06-$0.12-$0.06-$0.12$32.37 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTSAkoustis TechnologiesN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTSAkoustis Technologies1.000.320.28AMRNAmarinN/A3.232.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTSAkoustis Technologies28.84%AMRNAmarin22.25%Insider OwnershipCompanyInsider OwnershipAKTSAkoustis Technologies3.30%AMRNAmarin1.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTSAkoustis Technologies210154.59 million149.49 millionOptionableAMRNAmarin360410.67 million402.62 millionOptionableAKTS and AMRN HeadlinesRecent News About These CompaniesAmarin Corporation’s Earnings Call: A Mixed OutlookMarch 12 at 8:12 PM | tipranks.comAmarin Plc (AMRN) Q4 2024 Earnings Call TranscriptMarch 12 at 5:40 PM | finance.yahoo.comAmarin Corporation plc: Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) ProgramMarch 12 at 12:39 PM | finanznachrichten.deAmarin reports Q4 adjusted EPS (2c) vs. 0c last yearMarch 12 at 12:39 PM | markets.businessinsider.comAmarin announce splan to initiate ratio change under ADR programMarch 12 at 12:39 PM | markets.businessinsider.comAmarin drops despite Q4 beat amid ADS ratio changeMarch 12 at 12:39 PM | msn.comAmarin Corporation plc (AMRN) Q4 2024 Earnings Call TranscriptMarch 12 at 11:01 AM | seekingalpha.comAmarin expects cash to support continuing operations for ‘foreseeable future’March 12 at 7:34 AM | markets.businessinsider.comAmarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) ProgramMarch 12 at 7:34 AM | markets.businessinsider.comAmarin (NASDAQ:AMRN) Rating Increased to Hold at StockNews.comMarch 10 at 2:05 AM | americanbankingnews.comAmarin (NASDAQ:AMRN) Stock Rating Upgraded by StockNews.comMarch 8, 2025 | marketbeat.comAmarin (AMRN) Expected to Announce Quarterly Earnings on WednesdayMarch 5, 2025 | marketbeat.comAmarin’s vascepa shows cardiovascular efficacy in published trialFebruary 27, 2025 | markets.businessinsider.comAmarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol LoweringFebruary 27, 2025 | globenewswire.comAmarin (NASDAQ:AMRN) Stock Rating Lowered by StockNews.comFebruary 26, 2025 | marketbeat.comAmarin receives national reimbursement for VAZKEPA in AustriaFebruary 26, 2025 | markets.businessinsider.comAmarin Receives National Reimbursement for VAZKEPA® in AustriaFebruary 25, 2025 | markets.businessinsider.comAmarin Co. plc (NASDAQ:AMRN) Shares Acquired by Waterfront Wealth Inc.February 22, 2025 | marketbeat.comAmarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025February 19, 2025 | globenewswire.comFY2025 Earnings Estimate for Amarin Issued By Zacks ResearchFebruary 15, 2025 | marketbeat.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for WeekJanuary 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKTS and AMRN Company DescriptionsAkoustis Technologies NASDAQ:AKTSAkoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States, Asia, Europe, and internationally. It operates through Foundry Fabrication Services and RF Filters segments. The Foundry Fabrication Services segment provides engineering review and backend packaging services. Its RF Filters segment sells amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was founded in 2013 and is headquartered in Huntersville, North Carolina.Amarin NASDAQ:AMRN$0.40 -0.07 (-14.94%) Closing price 04:00 PM EasternExtended Trading$0.40 0.00 (-0.52%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
